Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin, linagliptin, and gliclazide effects on renal hemodynamics in metformin-treated type 2 diabetes
NL-OMON48622Phase 4Active, not recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of empagliflozin, linagliptin and gliclazide in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Vrije University Medical Center. Primary endpoints: Glomerular filtration rate in fasting and postprandial state and Effective renal plasma flow in fasting and postprandial state. Started Dec 2017; status: active, not recruiting.
02
Drugs
empagliflozinlinagliptingliclazide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON48622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48622.